UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 30, 2018
ELANCO ANIMAL HEALTH INCORPORATED
(Exact Name of Registrant as Specified in its Charter)
Indiana |
|
001-38661 |
|
82-5497352 |
(State or Other Jurisdiction of
|
|
(Commission File Number) |
|
(I.R.S. Employer
|
2500 Innovation Way, Greenfield, Indiana
|
|
46140
|
Registrants telephone number including area code: 877 352-6261
N/A
(Former Name or Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Elanco Animal Health Incorporated (the Company) announced the appointment of Todd S. Young as Executive Vice President and Chief Financial Officer of the Company effective November 1, 2018. He will serve as the Companys principal financial officer.
Mr. Young joins Elanco from ACADIA Pharmaceuticals, a biopharmaceutical company, where he served as Executive Vice President and Chief Financial Officer since August 2016. From 2015 to 2016, Mr. Young served as Senior Vice President and Treasurer for Baxalta Incorporated, a global biopharmaceutical company. Prior to Baxalta, Mr. Young worked for over 14 years at Baxter International, Inc., a global diversified healthcare company, holding multiple leadership roles, including Corporate Vice President and Treasurer from 2013 to 2015.
The Company entered into an employment offer letter with Mr. Young (the Offer Letter), as well as a Retention Bonus Agreement (the Bonus Agreement). The following description of the terms of Mr. Youngs employment is qualified in its entirety by reference to the complete terms and conditions of the Offer Letter and the Bonus Agreement, which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K.
Mr. Young will receive an annual base salary of $550,000. He will be eligible for an annual cash performance bonus with a bonus target of 70% of his base salary and for annual equity awards under Elanco 2018 Stock Plan with a target award value of $1,200,000. The terms of the annual equity awards are expected to be consistent with the annual award program for other senior executives. Mr. Young will be eligible to participate in the Companys benefit plans, all in accordance with the Companys customary terms and policies and consistent with other executives.
In connection with the commencement of Mr. Youngs employment, he will receive two one-time sign-on awards consisting of a $200,000 cash retention bonus that would be earned over a three-year period, and a restricted stock unit award valued at $300,000 that will vest in equal installments on each of the first two anniversaries of the grant date, expected to be in December 2018. Mr. Young will also be reimbursed for relocation costs.
There are no material arrangements or understandings between Mr. Young and any other person pursuant to which he was appointed as an officer of the Company. Mr. Young does not have any family relationship with any director or officer of the Company or any person nominated or chosen by the Company to become a director or executive officer, and there are no transactions in which Mr. Young has an interest requiring disclosure under Item 404(a) of Regulation S-K.
Concurrent with the effective date of the appointment of Mr. Young, Lucas Montarce will cease performing his day-to-day activities as Interim Chief Financial Officer of the Company and will transition responsibilities to Mr. Young while returning to Eli Lilly & Company as vice president and CFO of Lillys International Business Unit.
Item 7.01 Regulation FD Disclosure
A copy of the press release announcing the appointment of Todd S. Young is attached to this Current Report on Form 8-K as Exhibit 99.1. The information contained in the accompanying Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. The information contained in the press release shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit 10.1 |
|
Exhibit 10.2 |
|
Exhibit 99.1 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
ELANCO ANIMAL HEALTH INCORPORATED |
|
|
|
|
|
|
|
Date: October 30, 2018 |
By: |
/s/ Michael-Bryant Hicks |
|
Name: |
Michael-Bryant Hicks |
|
Title: |
Executive Vice President, General Counsel and Corporate Secretary |
October 15, 2018
Todd Young
Dear Todd:
It is my pleasure to extend to you a formal offer of employment with Elanco US Inc. and to outline the provisions of that offer in detail. The position is Chief Financial Officer reporting to Jeff Simmons, President, CEO and Director, Elanco US Inc. This offer, and any modification, is contingent on approval by the Elanco Board of Directors and the Boards Compensation Committee and the other offer contingencies described below.
This offer includes an opportunity for continued professional challenge and growth and an attractive compensation and benefit package. You will begin employment with Elanco on or about November 1, 2018.
Estimated Annual Cash Compensation
Your annualized base salary will be $550,000 of course, prorated based on your start date in 2018. You will be eligible to receive consideration for a salary increase effective March 1, 2020.
In addition, you will be eligible to participate in The Elanco Bonus Plan, which provides the variable part of your total annual cash compensation. This annual incentive program for eligible employees is designed to align employee behaviors with company goals. The bonus is comprised generally of three components: (i) your individual bonus target, which is based on your job path, level and pay scale and is currently equal to 70% of your base salary earnings; (ii) company performance, which is currently measured by revenue growth and earnings growth; and (iii) your individual year-end performance rating.
You must remain actively employed through December 31 of each plan year to be eligible for a bonus payout. Your actual bonus payout can range from 0-200% of target and is made by the end of the first quarter of the following year.
Estimated Annual Equity Compensation
In addition to your base salary and bonus, you will be eligible to participate in the Elanco equity program which is designed to encourage decisions and actions in the best long-term interest of the company and to help you build equity in the company. In order to be eligible for an equity grant in February of each year, you need to be an active employee on the first business day in January and on the grant date and you must have met performance expectations during the prior years
performance period. The total value of your equity grants are subject to review each year and will vary based on several factors including your job level, individual performance and retention of critical skills. The form of equity awards and their associated performance metrics will be provided at the time of grant following approval by the Compensation Committee of the Elanco Board of Directors. Executive officers are subject to a share retention and share ownership policy. Under the policy, you must hold all net shares from equity award payouts for at least one year before selling and to hold shares valued at three times your annual base salary. Until the share requirement is attained, executive officers are deemed compliant with the policy if at least 30% of the net shares from payouts are retained.
Transitional Compensation
Retention Bonus:
You will receive a one-time Retention Bonus payment of $200,000, less applicable taxes, payable to you no later than 30 days from your first day of employment. Assuming you remain actively employed with Elanco for a 36 month continuous month period following your employment, you will have no repayment obligation for the Retention Bonus. Should you cease to be employed by the company prior to that time, you will be responsible for repaying a portion of the Retention Bonus on your last day with Elanco as described in the Retention Bonus Agreement. Please sign the enclosed retention bonus agreement and return it to Curtis Dorsey.
Restricted Stock Unit Grant:
In addition to your annual Elanco equity program eligibility, you will receive a one-time award of $300,000 of Restricted Stock Units (RSUs) in December 2018. RSUs are an outright award of shares of stock that are provided to you if you remain employed with the company for a specified restriction (or vesting) period and sufficiently meet job expectations. A portion (50%) are scheduled to vest one (1) year from the grant date month. The final 50% are scheduled to vest in two (2) years from the grant date month.
Relocation Program
You also will be eligible for Elancos comprehensive Relocation Program. The program is intended to assist transferring employees and their families by providing comprehensive relocation benefits to facilitate your move and minimize personal disruption. In general, relocating employees are eligible to receive U.S. home sale assistance, home purchase assistance, transportation of household goods, temporary living and final move support consistent with the companys relocation policies. Homeowners are eligible for a $6,000 (net) relocation allowance (renters are eligible for a $3,000 (net) relocation allowance) to be used at your discretion to pay for items not covered by the companys relocation program. This allowance is considered taxable income and will be grossed-up. This benefit will be available for up to 12 months from the start of your employment.
A document explaining the relocation program in its entirety is enclosed as well as the Relocation Expense Assignment Agreement.
Comprehensive Benefit Program
The Lilly Employee 401(k) Plan provides an important component of your retirement income. You may contribute up to 50% of your monthly base salary up to the IRS maximum and choose among several different investment options. You will have the opportunity to select between (1) investing in a Target Date Portfolio a portfolio that is geared toward the year you expect to start withdrawing your money and gradually shifts the investment mix as you get closer to that time or (2) building and maintaining your own portfolio by selecting from a variety of investment funds, including a self-directed mutual fund window that allows you to invest in mutual and other funds. Contributions to the plan may be made on a pre-tax basis. In addition, the plan offers a Roth 401(k) feature that allows participants to contribute on an after-tax basis. The company currently provides a fixed monthly matching contribution to participants equal to a dollar for each dollar you contribute up to 6% of your monthly base salary (up to the IRS maximum). These contributions are automatically invested consistent with your own investment choices under the plan. Participants become vested in employer contributions following two years of service and can diversify company-matching contributions to other investments. You also can increase your contribution rate automatically each year and automatically rebalance your 401(k) assets. Beginning January 1, 2019, you will be eligible to participate in The Elanco Employee 401(k) Plan instead. In addition to the features described above that will be available in The Elanco Employee 401(k) Plan, the Elanco 401(k) also will offer an employer contribution equal to 3% of your base pay at the end of each calendar year, provided you remain employed by Elanco as of December 31. This additional matching contribution does not depend on your contribution rate to the 401(k).
Medical Coverage choices currently include two consumer directed health care options at a low monthly cost for you and/or your family. Your Pharmacy Card enables you to participate in Lillys prescription drug benefit and, in addition, Lilly currently provides dental and vision benefits at a low monthly cost.
Life Insurance provided by the company is another benefit for employees. You are currently eligible for a death benefit equal to two times your annual base salary ($1,100,000) and business travel accident insurance equal to three times your annual base salary ($1,650,000) at no cost. You also can purchase additional term life insurance (up to five times your annual base salary) at group insurance premium rates. With this supplemental coverage, you can acquire up to seven times your annual base salary of life insurance coverage per year.
As we prepare to become an independent company, we expect new, Elanco-sponsored benefit programs to become effective over the next 18 months.
Offer Contingencies :
As a part of our employment process, your offer is contingent upon the following conditions:
· Successful completion of a drug screen evaluation provided by the company;
· Satisfying Elancos background check requirements, including but not limited to an acceptable criminal background check, educational verification and motor vehicle report (for positions required to have a fleet vehicle);
· Proof of identity, eligibility, and authorization to be lawfully employed in the United States;
· Compliance with The Red Book Code of Business Conduct including its training due within 30 calendar days of your start date;
· Signature and completion of the Employee Confidentiality and Invention Agreement due within 30 calendar days of your start date;
· Evaluation and approval of any potential conflict of interest (e.g., board or committee service for a company involved in healthcare or matters related to Elancos business);
· Your acceptance of this offer by no later than Noon (ET), Monday, October 22, 2018.
To accept Elancos offer of employment, please sign and return the attached Letter of Acceptance by Noon (ET), Monday, October 22, 2018. Of course, this offer letter is not an employment agreement; you will be an at will employee should you join the company. If any questions arise, or I can provide help in any way, please contact me at the number below.
I am confident that you have much to contribute to our team at Elanco, and Elanco has much to offer you in return. For more than 60 years, Elanco has flourished because our corporate culture actively supports the talents of people at every level of the organization through our commitment to the personal development of each employee.
Sincerely, |
|
|
|
|
|
/s/ David Kinard |
|
David Kinard |
|
Executive Vice President, Human Resources and Corporate Affairs |
|
Elanco Animal Health, Incorporated |
|
|
|
Enclosures |
ELANCO US Inc.
TOTAL COMPENSATION AND BENEFIT PROGRAMS(1)
Estimated Annualized Cash Compensation |
|
|
|
|
Annual Base Compensation
|
|
$ |
550,000 |
|
Estimated Bonus at Target 70% |
|
$ |
385,000 |
* |
(1) Keep in mind that the company reserves the right to amend, modify or terminate its compensation and benefit programs at any time in its sole discretion. In the event of any conflict between the information included in this offer and the terms of Elancos compensation and benefits plans, the terms of the plans will control.
Additional Company Benefits
· Medical and Dental Insurance
· Reimbursement Accounts
· Illness Pay
· Disability
· Credit Union
· Financial Planning Service
· Relocation Plan (See enclosed brochure)
· Employee Activities
· Vacation (12 hours per month); vacation hours are prorated based on your start dates
· Holiday Plan (7 days per year: New Years Day, Memorial Day, Independence Day, Labor Day, Thanksgiving, Day after Thanksgiving, Christmas)
· Floating Holiday (3 days per year; the Company reserves the right to designate dates for the Floating Holiday)
· Year End Closure (working days between Christmas and next New Years Day)
Optional Employee-Paid Benefits
· Supplemental Life Insurance
· Dependent Life Insurance
· Flexible CarePlus (life/long-term care insurance)
· Additional vacation purchase
LETTER OF ACCEPTANCE
TO: |
|
Curtis Dorsey |
|
|
Global Recruiting and Human Resources |
|
|
Elanco US Inc. |
|
|
2500 Innovation Way |
|
|
Greenfield, IN 46140 |
|
|
|
FROM: |
|
Todd Young |
I am pleased to accept your offer of employment with Elanco US Inc., as described in your letter dated October 15, 2018. It is my understanding that my position will be Chief Financial Officer reporting to Jeff Simmons, President, CEO and Director, Elanco US Inc. I look forward to receiving additional details regarding my on-boarding process with Elanco and to becoming a valued contributor to the Elanco Team.
Sincerely,
Signature: |
/s/ Todd Young |
|
|
|
|
Date of Birth (MM/DD/YYYY): |
|
|
|
|
|
Current Date: |
10-15-2018 |
|
|
|
|
Anticipated Start Date: |
Nov. 1 |
|
Please email a signed copy to my attention at cdorsey@Elanco.com
NOTE: THIS OFFER EXPIRES AT Noon (ET), Monday, October 22, 2018
Retention Bonus Agreement
This Retention Bonus Agreement (Agreement) is entered into and effective this 18 day of Oct., 2018, by and between Todd Young (Mr. Young) and Elanco US Inc. (Elanco), an Indiana corporation having its principal offices in Greenfield, Indiana.
RECITALS
1. Mr. Young will be employed by Elanco beginning on or about November 1, 2018, as a Chief Financial Officer.
2. Elanco has agreed to provide a one-time payment to Mr. Young in accordance with the terms of this Agreement provided that Mr. Young works actively for Elanco for at least three (3) continuous years from the date of employment.
AGREEMENT
In consideration of the premises, the mutual covenants and agreements herein, and each act performed and to be performed hereunder, Elanco and Mr. Young agree as follows:
1. Elanco agrees to make a one-time payment to Mr. Young equal to the maximum principal sum of two hundred thousand dollars ($200,000) (the Retention Bonus) less all applicable taxes. The Retention Bonus will be made to Mr. Young no later than during his first month of employment.
2. The parties agree to the following terms of repayment:
If Mr. Young completes thirty-six (36) continuous months of active employment at Elanco, Mr. Young will have no repayment obligation of the Retention Bonus. Except as described below, if Mr. Young ceases employment with Elanco for any reason before completing the full thirty-six (36) continuous months of active employment, Mr. Young will be obligated to repay a portion of the Retention Bonus to Elanco as designated by the following schedule:
Months Completed of
|
|
Repayment Amount
|
|
|
|
1-11 |
|
100% of the Retention Bonus |
|
|
|
12-23 |
|
67% of the Retention Bonus |
|
|
|
24-35 |
|
33% of the Retention Bonus |
|
|
|
36 months or greater |
|
0% |
If Mr. Young ceases to be employed by Elanco before the full period described above, then the remaining portion of the Retention Bonus described above (Unpaid Balance) will be immediately due and payable, without notice, and Mr. Young will pay to Elanco on the date he ceases to be employed by Elanco the entire Unpaid Balance existing on that date. Notwithstanding the foregoing, however, in the event that Mr. Young ceases to be employed by Elanco and, as a result, becomes eligible for a severance payment under the Eli Lilly and Company Change in Control Severance Pay Plan For Select Employees or in the event Mr. Young is terminated involuntarily as a result of his failure to locate a position following reallocation, medical reassignment or a plant closing or reduction in workforce, as determined by Elanco, Mr. Young will have no further repayment obligation.
3. Mr. Young hereby promises to pay the Unpaid Balance in full on the date it becomes due and payable under paragraph 2 above. If Mr. Young fails to pay the Unpaid Balance in full when due (a Default), then from and after the due date until the Unpaid Balance is paid in full, the Unpaid Balance will bear interest, compounded annually, at a rate equal to two percent (2%) plus the prime rate in effect on the stated due date at the Elements Financial, Indianapolis, Indiana (Default Interest). Default Interest will be due and payable as it accrues.
4. If Mr. Young dies before he completes the 36 month period of active employment described above, Mr. Young will have no repayment obligation.
5. If Mr. Young becomes disabled, as determined by Elanco, before he completes the full 36 month period of active employment described above, any period of disability will be treated as active employment for purposes of paragraph 2 above.
6. To the extent permitted by applicable law, Mr. Young agrees to pay all costs of collection and enforcement of this Agreement, whether or not suit is filed, including, but not limited to, reasonable attorneys fees, legal expenses, and court costs.
7. In the event Mr. Youngs employment with Elanco ceases and a Default has occurred and remains uncured, Mr. Young hereby authorizes Elanco to deduct from any wages or other compensation then or thereafter owed to Mr. Young, an amount not to exceed the Unpaid Balance plus all Default Interest accrued through the date the deduction is made to the maximum extent permitted by law. This payroll deduction authorization may be revoked at any time by Mr. Young by a subsequent writing delivered to the Manager of Employee Financial Services at Lilly.
8. This Agreement is not an employment agreement.
9. This Agreement will be governed by and construed in accordance with the laws of the State of Indiana.
On Behalf of
Elanco US Inc.
By |
|
|
|
|
|
|
|
|
/s/ David S. Kinard |
|
10/15/18 |
David S. Kinard |
|
Date |
Executive Vice President |
|
|
Human Resources and Corporate Affairs |
|
|
|
|
|
|
|
|
/s/ Todd Young |
|
10-18-18 |
Todd Young |
|
Date |
|
|
|
|
|
Media Contact: Colleen Parr Dekker 1-317-989-7011 parr_dekker_colleen@elanco.com |
Elanco Names Todd S. Young as New Chief Financial Officer
Young to join Indiana-based Animal Health Companys Leadership Team
Greenfield, Ind. (October 30, 2018) Elanco Animal Health Incorporated (NYSE: ELAN), today named Todd S. Young as executive vice president and chief financial officer (CFO), joining Elancos Executive Committee and reporting to Elanco president and chief executive officer, Jeffrey N. Simmons.
Young starts his new position at Elanco on November 1 at the companys Greenfield, Indiana headquarters. Lucas Montarce, who has been serving as acting Elanco CFO, will return to Eli Lilly and Company as vice president and CFO of Lillys International Business Unit.
I am pleased to welcome Todd to the Elanco Executive Team, said Jeff Simmons, president and CEO of Elanco. His deep financial expertise combined with his pharmaceutical industry knowledge make him an excellent addition to Elanco at this exciting time in our companys history. We also thank Lucas Montarce for his dedication and commitment stepping in during a critical time.
Young will have responsibility for Elancos financial operations. He has more than 20 years experience in a wide range of financial roles. Most recently, he was executive vice president and CFO for ACADIA Pharmaceuticals Inc. in San Diego. He also spent several years in varying financial leader roles at Baxter International and worked on the spin-off of Baxalta, which he then joined as senior vice president and treasurer. He started his career at law firm Sidley Austin L.L.P.
Over the past 20 years, Young has had experience in all sectors of corporate financial operations, including tax, treasury, mergers and acquisitions, and leading and building finance teams. He also spent time in international markets throughout his career.
About Elanco Animal Health
Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, were driven by our vision of food and companionship enriching life all to advance the health of animals, people and the planet. Learn more at www.elanco.com.
####